Ipsen announces that the CHMP of the European Medicines Agency has recommended, following its review of data from the MOVE trial, that no marketing authorization be granted for the experimental palovarotene in fibrodysplasia ossificans progressiva.

An ultra-rare disease, fibrodysplasia ossificans progressiva (FOP) is characterized by progressive and permanent abnormal bone formation. Ultimately, this disease shortens median life expectancy to 56 years.

Pointing out that there are currently only symptomatic treatments for FOP in the EU, Ipsen will request a re-examination of the CHMP opinion, based on scientific data from the existing palovarotene clinical trial program.

Copyright (c) 2023 CercleFinance.com. All rights reserved.